References
- Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 2005; 41:634-53. doi:https://doi.org/10.1086/432579. PMID:16080086
- Adam RD, Hunter G, DiTomasso J, Comerci G Jr. Mucormycosis: Emerging prominence of cutaneous infections. Clin Infect Dis. 1994;19:67-76. doi:https://doi.org/10.1093/clinids/19.1.67. PMID:7948560
- Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, Bitar D, Dromer F, Lortholary O; French Mycosis Study Group. A global analysis of mucormycosis in France: The RetroZygo study (2005-2007). Clin Infect Dis. 2012;54 Suppl 1:S35-43. doi:https://doi.org/10.1093/cid/cir880. PMID:22247443
- Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P, et al. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859-67. doi:https://doi.org/10.1111/j.1469-0691.2010.03456.x. PMID:21199154
- Pana ZD, Seidel D, Skiada A, Groll AH, Petrikkos G, Cornely OA, Roilides E; Collaborators of Zygomyco.net and/or FungiScope™ Registries. Invasive mucormycosis in children: An epidemiologic study in European and non-European countries based on two registries. BMC Infect Dis. 2016;16:667; doi:https://doi.org/10.1186/s12879-016-2005-1. PMID:27832748
- de A. Santiago ALCM, Hoffmann K, Lima DX, de Oliveira RJV, Vieira HEE, Malosso E, et al. A new species of Lichtheimia (Mucoromycotina, Mucorales) isolated from Brazilian soil. Mycol Prog. 2014;13:343-52. doi:https://doi.org/10.1007/s11557-013-0920-8.
- Alastruey-Izquierdo A, Hoffmann K, de Hoog GS, Rodriguez-Tudela JL, Voigt K, Bibashi E, Walther G. Species recognition and clinical relevance of the zygomycetous genus Lichtheimia (syn. Absidia pro parte, Mycocladus). J Clin Microbiol. 2010;48:2154-70. doi:https://doi.org/10.1128/JCM.01744-09. PMID:20357218
- Schwartze VU, Hoffmann K, Nyilasi I, Papp T, Vagvolgyi C, de Hoog S, Voigt K, Jacobsen ID. Lichtheimia species exhibit differences in virulence potential. PloS One. 2012;7:e40908; doi:https://doi.org/10.1371/journal.pone.0040908. PMID:22911715
- Schwartze VU, Santiago AL, Jacobsen ID, Voigt K. The pathogenic potential of the Lichtheimia genus revisited: Lichtheimia brasiliensis is a novel, non-pathogenic species. Mycoses. 2014;57 Suppl 3:128-31. doi:https://doi.org/10.1111/myc.12230. PMID:25267009
- Kamei K. Animal models of zygomycosis–Absidia, Rhizopus, Rhizomucor, and Cunninghamella. Mycopathologia. 2001;152:5-13. doi:https://doi.org/10.1023/A:1011900630987. PMID:11694096
- Ibrahim AS, Gebremariam T, Lin L, Luo G, Husseiny MI, Skory CD, Fu Y, French SW, Edwards JE Jr., Spellberg B The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol. 2010;77:587-604. doi:https://doi.org/10.1111/j.1365-2958.2010.07234.x. PMID:20545847
- Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest. 1984;74:150-60. doi:https://doi.org/10.1172/JCI111395. PMID:6736246
- Ibrahim AS, Gebremariam T, Luo G, Fu Y, French SW, Edwards JE Jr., Spellberg B. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrob Agents Chemother. 2011;55:1768-70. doi:https://doi.org/10.1128/AAC.01577-10. PMID:21263057
- Salas V, Pastor FJ, Calvo E, Alvarez E, Sutton DA, Mayayo E, Fothergill AW, Rinaldi MG, Guarro J. In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: Poor efficacy of posaconazole. Antimicrob Agents Chemother. 2012;56:2246-50. doi:https://doi.org/10.1128/AAC.05956-11. PMID:22290952
- Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother. 2010;54:1298-304. doi:https://doi.org/10.1128/AAC.01222-09. PMID:20038620
- Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence. 2011;2:348-55. doi:https://doi.org/10.4161/viru.2.4.17074. PMID:21788730
- Luo G, Gebremariam T, Lee H, French SW, Wiederhold NP, Patterson TF, Filler SG, Ibrahim AS. Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis. Antimicrob Agents Chemother. 2013;57:3340-7. doi:https://doi.org/10.1128/AAC.00313-13. PMID:23650163
- Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE Jr, Spellberg BJ. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117:2649-57. doi:https://doi.org/10.1172/JCI32338. PMID:17786247
- Slesiona S, Ibrahim-Granet O, Olias P, Brock M, Jacobsen ID. Murine infection models for Aspergillus terreus pulmonary aspergillosis reveal long-term persistence of conidia and liver degeneration. J Infect Dis. 2012;205:1268-77. doi:https://doi.org/10.1093/infdis/jis193. PMID:22438397
- Spellberg B, Edwards J Jr., Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556-69. doi:https://doi.org/10.1128/CMR.18.3.556-569.2005. PMID:16020690
- Kontoyiannis DP, Yang H, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: A retrospective study. BMC Infect Dis. 2016;16:730; doi:https://doi.org/10.1186/s12879-016-2023-z. PMID:27905900
- Gebremariam T, Lin L, Liu M, Kontoyiannis DP, French S, Edwards JE Jr., Filler SG, Ibrahim AS. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J Clin Invest. 2016;126:2280-94. doi:https://doi.org/10.1172/JCI82744. PMID:27159390
- Winzell MS, Ahren B. The high-fat diet-fed mouse: A model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes. 2004;53 Suppl 3:S215-9. doi:https://doi.org/10.2337/diabetes.53.suppl_3.S215. PMID:15561913
- Kitada M, Ogura Y, Koya D. Rodent models of diabetic nephropathy: Their utility and limitations. Int J Nephrol Renovasc Dis. 2016;9:279-90. doi:https://doi.org/10.2147/IJNRD.S103784. PMID:27881924
- Luo G, Gebremariam T, Clemons KV, Stevens DA, Ibrahim AS. Heat-killed yeast protects diabetic ketoacidotic-steroid treated mice from pulmonary mucormycosis. Vaccine. 2014;32:3573-6. doi:https://doi.org/10.1016/j.vaccine.2014.04.086. PMID:24814556
- Liu M, Spellberg B, Phan QT, Fu Y, Fu Y, Lee AS, Edwards JE Jr, Filler SG, Ibrahim AS. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010;120:1914-24. doi:https://doi.org/10.1172/JCI42164. PMID:20484814
- Budnik I, Shenkman B, Hauschner H, Zilinsky I, Savion N. Role of heterotrimeric G proteins in platelet activation and clot formation in platelets treated with integrin alphaIIbbeta3 inhibitor. Platelets. 2017:1-5. [Advance online publication]. doi:https://doi.org/10.1080/09537104.2017.1295136. PMID:28406726.
- Varon D, Shai E. Platelets and their microparticles as key players in pathophysiological responses. J Thromb Haemost. 2015;13 Suppl 1:S40-6. doi:https://doi.org/10.1111/jth.12976. PMID:26149049
- Warkentien T, Rodriguez C, Lloyd B, Wells J, Weintrob A, Dunne JR, Ganesan A, Li P, Bradley W, Gaskins LJ, et al. Invasive mold infections following combat-related injuries. Clin Infect Dis. 2012;55:1441-9. doi:https://doi.org/10.1093/cid/cis749. PMID:23042971
- Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P, et al. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859-67. doi:https://doi.org/10.1111/j.1469-0691.2010.03456.x. PMID:21199154
- Dannaoui E, Mouton JW, Meis JF, Verweij PE, Eurofung N. Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. Antimicrob Agents Chemother. 2002;46:1953-9. doi:https://doi.org/10.1128/AAC.46.6.1953-1959.2002. PMID:12019114
- Ben-Ami R, Lewis RE, Kontoyiannis DP. Enemy of the (immunosuppressed) state: An update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol. 2010;150:406-17. doi:https://doi.org/10.1111/j.1365-2141.2010.08283.x. PMID:20618330
- Spellberg B, Fu Y, Edwards JE Jr., Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49:830-2. doi:https://doi.org/10.1128/AAC.49.2.830-832.2005. PMID:15673781
- Gebremariam T, Liu M, Luo G, Bruno V, Phan QT, Waring AJ, Edwards JE Jr, Filler SG, Yeaman MR, Ibrahim AS. CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest. 2014;124:237-50. doi:https://doi.org/10.1172/JCI71349. PMID:24355926
- Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE Jr. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun. 2005;73:778-83. doi:https://doi.org/10.1128/IAI.73.2.778-783.2005. PMID:15664916
- Chibucos MC, Soliman S, Gebremariam T, Lee H, Daugherty S, Orvis J, Shetty AC, Crabtree J, Hazen TH, Etienne KA, et al. An integrated genomic and transcriptomic survey of mucormycosis-causing fungi. Nature Commun. 2016;7:12218; doi:https://doi.org/10.1038/ncomms12218. PMID:27447865
- Schwartze VU, Winter S, Shelest E, Marcet-Houben M, Horn F, Wehner S, Linde J, Valiante V, Sammeth M, Riege K, et al. Gene expansion shapes genome architecture in the human pathogen Lichtheimia corymbifera: An evolutionary genomics analysis in the ancient terrestrial mucorales (Mucoromycotina). PLoS Genet. 2014;10:e1004496; doi:https://doi.org/10.1371/journal.pgen.1004496. PMID:25121733
- Simitsopoulou M, Roilides E, Maloukou A, Gil-Lamaignere C, Walsh TJ. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes. Mycoses. 2008;51:147-54. doi:https://doi.org/10.1111/j.1439-0507.2007.01457.x. PMID:18254752
- Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis. 2005;191:1180-7. doi:https://doi.org/10.1086/428503. PMID:15747255
- Reinhardt DJ, Licata I, Kaplan W, Ajello L, Chandler FW, Ellis JJ. Experimental cerebral zygomycosis in alloxan-diabetic rabbits: Variation in virulence among zygomycetes. Sabouraudia. 1981;19:245-56. doi:https://doi.org/10.1080/00362178185380421. PMID:6798698